Published on in Vol 11, No 5 (2022): May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34711, first published .
Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

Gilmar Gutierrez 1, BSc;  Joshua Rosenblat 2, MD;  Emily Hawken 3, MSc, PhD;  Jennifer Swainson 4, MD;  Gustavo Vazquez 3, MD, PhD

1 School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON, CA

2 Canadian Rapid Treatment Center of Excellence , Toronto, ON, CA

3 Department of Psychiatry, Faculty of Health Sciences, Queen's University, Kingston, ON, CA

4 Department of Psychiatry, University of Alberta , Edmonton, AB, CA

Corresponding Author:

  • Gustavo Vazquez, MD, PhD
  • Department of Psychiatry
  • Faculty of Health Sciences
  • Queen's University
  • 15 Arch Street
  • Kingston, ON
  • CA
  • Phone: 1 6135444900
  • Email: g.vazquez@queensu.ca